Tuoxin Pharmaceutical

Henan Tuoxin Pharmaceutical Co., Ltd. is a prominent Chinese pharmaceutical company specializing in the research, development, and large-scale production of nucleoside-based Active Pharmaceutical Ingredients (APIs) and chemical intermediates. Founded in 2001 and headquartered in Xinxiang, the company has established itself as a global leader in the nucleoside industry, integrating chemical synthesis with biological fermentation technologies. Tuoxin gained international recognition as the primary manufacturer of the API for Azvudine, the first domestically developed oral antiviral treatment for COVID-19 in China. Their product portfolio includes essential antiviral and anti-tumor agents such as Ribavirin, Inosine, and Cytosine. Listed on the Shenzhen Stock Exchange, the company operates high-standard GMP manufacturing facilities and serves a broad client base across the global pharmaceutical supply chain.